← All diseases Infectious diseases

Chronic hepatitis C

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (76)Meta-analysis (20)Treatment guideline (4)Phase 3 study (24)Randomized trial (14)Systematic review (14)Clinical trial (680)Review article (146)Early study (phase 1 or 2) (11)Case report (85)Laboratory or animal study (8)Commentary or editorial (53)Retracted publication (2) Studies currently recruiting participants only (15)

Filter

Publications and studies (1942)

• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Immune Checkpoint Inhibitors Suppress Hepatitis C Virus Replication in Infected Patients With Solid Tumors. (2023/09/01) ♡
• Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study. (2023/09/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Evaluation and Comparison of Serum Vitamin D Levels between Injection Drug Users with and without Chronic Hepatitis C Infection in Hamadan-Iran. (2023/09/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Incidental Finding of Hepatic Inflammatory Pseudotumor Immunoglobulin G4-Related Disease With Underlying Chronic Hepatitis C. (2023/08/24) ♡
• Reduction in Racial and Ethnic Disparity in Survival Following Liver Transplant for Hepatocellular Carcinoma in the Direct-acting Antiviral Era. (2023/08/01) ♡
• HCV Core Protein-ISX Axis Promotes Chronic Liver Disease Progression via Metabolic Remodeling and Immune Suppression. (2023/08/01) ♡
• Hepatitis C Treatment Initiation Among US Medicaid Enrollees. (2023/08/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Acute hearing and visual loss caused by thiamine deficiency. (2023/07/31) ♡
• Efficiency and safety of sofosbuvir in Bangladeshi children with chronic hepatitis C virus infection. (2023/07/28) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Vitamin D supplementation and serum markers associated with hepatic fibrogenesis in chronic hepatitis C patients: A summary of clinical evidences from a tropical country with a high incidence of hepatitis-related hepatocellular carcinoma. (2023/07/01) ♡
• HIGH-DENSITY LIPOPROTEIN CHOLESTEROL AND SYSTEMIC ARTERIAL HYPERTENSION ARE ASSOCIATED WITH HEPATIC NECROINFLAMMATORY ACTIVITY IN PATIENTS WITH CHRONIC HEPATITIS C. (2023/07/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Minimal monitoring is a safe but underutilised strategy for hepatitis C virus management in Singapore. (2023/06/27) ♡
• The advantages of drinking mineral water in the rehabilitation of patients with viral hepatitis C with accompanying non-alcoholic fatty liver disease after suffering from COVID-19. (2023/06/26) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Antiviral Treatment of Coronavirus Disease-2019 Pneumonia. (2023/06/01) ♡
• Cost-effectiveness and economic investment to eliminate chronic hepatitis C in Mexico. (2023/06/01) ♡
• Hepatitis C screening and detection program in a large population: Epidemiological transition and characterization of the disease. (2023/06/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Sarcopenia in chronic viral hepatitis: From concept to clinical relevance. (2023/05/27) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Eight versus twelve weeks of sofosbuvir-velpatasvir in treatment-naïve non-cirrhotic patients with chronic hepatitis C virus infection: Study protocol for a multicentric, open labelled, randomized, non-inferiority trial (RESOLVE trial). (2023/05/18) ♡
• Association of Viral Hepatitis Status and Post-hepatectomy Outcomes in the Era of Direct-Acting Antivirals. (2023/05/01) ♡
• Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post-unrestricted availability of direct acting antiviral therapies. (2023/05/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. ASO Author Reflections: Viral Hepatitis on Post-Hepatectomy Outcomes in the Direct-Acting Antivirals Era. (2023/05/01) ♡
• Improved Liver Function After Sustained Virologic Response Enhanced Prognosis in Hepatitis C with Compensated Advanced Liver Fibrosis. (2023/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatitis C Virus Cascade of Care Among Perinatal Patients in Maine Diagnosed With Opioid Use Disorder, 2015-2020. (2023/05/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. A Rare Case of Nephrotic Syndrome in the Setting of Sjogren Syndrome-related Cryoglobulinemic Vasculitis. (2023/05/01) ♡
• ANGPTL4 is a potential driver of HCV-induced peripheral insulin resistance. (2023/04/25) ♡
• Impact of direct-acting antiviral treatment for hepatitis C on cardiovascular diseases and extrahepatic cancers. (2023/04/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Recurrence of hepatocellular carcinoma after radiofrequency ablation in a poor-risk patient with chronic renal failure and other complications successfully treated with stereotactic body radiotherapy. (2023/04/01) ♡
• The Cost-effectiveness of Transplanting Hearts From Hepatitis C-infected Donors Into Uninfected Recipients. (2023/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. (2023/04/01) ♡
• Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism. (2023/03/30) ♡
• AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2. (2023/03/13) ♡
• Author Correction: Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies. (2023/03/08) ♡
• Risk of metabolic syndrome in patients with chronic hepatitis C. (2023/03/05) ♡
• Early post-liver transplant use of direct-acting antivirals in naive and NS5A inhibitor-experienced HCV patients. (2023/03/01) ♡
• Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates. (2023/03/01) ♡
• Evaluation of treatment access and scope of a multistate hepatitis C virus Extension for Community Healthcare Outcomes telehealth service in the US Indian Health System, 2017-2021. (2023/03/01) ♡
• Selective profiling of liver-related specific proteins based on sofosbuvir-modified magnetic separation material. (2023/03/01) ♡
• Prevalence of hepatitis C virus infection among men who have sex with men with human immunodeficiency virus-1 infection between 2010 and 2020 in Japan: A single-center retrospective cohort study. (2023/03/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Response to antiviral therapy for chronic hepatitis C and risk of hepatocellular carcinoma occurrence in Japan: a systematic review and meta-analysis of observational studies. (2023/03/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD). (2023/03/01) ♡
• Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C. (2023/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Hepatocellular carcinoma and hepatitis C virus treatments: The bold and the beautiful. (2023/02/01) ♡
• The role of serum sphingolipids as potential biomarkers of non-response to direct acting antiviral therapy in chronic hepatitis C virus infection. (2023/02/01) ♡
• Targeted protein degradation as an antiviral approach. (2023/02/01) ♡
• Fib-4 index predicts prognosis after achievement of sustained virologic response following direct-acting antiviral treatment in patients with hepatitis C virus infection. (2023/02/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Management of in- and out-of-hospital screening for hepatitis C. (2023/01/25) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial: chronic hepatitis C with metabolic dysfunction-associated fatty liver disease - a model for adoption of Sustainable Development Goal 3. (2023/01/01) ♡
• Barriers and facilitators to implementing a Pharmacist, Physician, and Patient Navigator-Collaborative Care Model (PPP-CCM) to treat hepatitis C among people who inject drugs. (2023/01/01) ♡
• Meta-analysisiAll studies on one question combined and calculated together. This is the strongest form of research that exists: a single loose study can be coincidence, dozens together much less so. The label says something about the design, not about the outcome — which can also be that something does NOT work. Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis. (2023/01/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Artificial Intelligence in Hepatology- Ready for the Primetime. (2023/01/01) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.